Autologous intraarterial pancreatic bone-marrow mononuclear cells infusion in T2D patients: Changes on beta-cells function, insulin resistance, and inflammatory marker

• DOI: 10.1016/j.retram.2023.103437
• Publication Date: 2023-12-29T03:02:42Z
• Authors: Farid Kurniawan; Imam Subekti; Em Yunir; Dante Saksono Har...; Dyah Purnamasari; Tri Juli Edi Tarigan; Wismandari Wisnu; Dicky Levenus Tah...; Syahidatul Wafa; Cindy Astrella; Eunike Vania Chri...; Anna Mira Lubis; Ika Prasetya Wijaya; Birry Karim; Mohamad Syahrir A...; Indrati Suroyo; Sahat Matondang; Krishna Pandu Wic...; Dewi Wulandari; Iqbal Fasha; Cynthia Retna Sar...; Cosphiadi Irawan; Pradana Soewondo

Type 2 diabetes (T2D) is a progressive disease. Many drugs currently being used for the management of T2D have minimal effect on pancreatic beta cells regeneration. Cell-based therapies might provide potential benefits in this aspect.A pilot study in five T2D patients with 12 months follow-up was performed to evaluate the effect of autologous bone marrow mononuclear stem cells (BM-MNCs) infusion into pancreatic arteries on the insulin requirement, beta-cell function, insulin resistance, and systemic inflammatory marker (CRP).The primary endpoint, a 50 % reduction of total insulin doses from baseline, was not achieved in this study. However, a trend of increasing fasting C-peptide (p = 0.07) and C-peptide 60' (p = 0.07) and 90' (p = 0.07) after a mixed-meal tolerance test was observed 12 months post-infusion compared to baseline levels. A similar result was observed for the homeostatic model assessment of beta cell function (HOMA1-B), an index for beta cell function. No improvement was observed for insulin resistance measured by homeostasis model assessment of insulin resistance (HOMA1-IR) and systemic inflammatory parameter.Intraarterial pancreatic autologous BM-MNCs infusion might potentially improve beta cell function in T2D patients, although further study is needed to confirm this finding.